Comparison of clinical efficacy between chrono-chemotherapy and conventional chemotherapy in patients with non-small cell lung cancer.

This work focused on the clinical efficacy of chrono-chemotherapy and conventional chemotherapy on patients with non-small cell lung cancer (NSCLC), providing a theoretical basis for the clinical promotion of chrono-chemotherapy. 60 NSCLS patients in our hospital were randomly enrolled into a chrono-chemotherapy group and a conventional chemotherapy group, with 30 cases in each. Patients were treated with the standardized first-line treatment TP regimen (paclitaxel + cisplatin). After two cycles of chemotherapy, the clinical efficacy and adverse reactions of patients receiving various methods were observed. After the chemotherapy, CD3+, CD4+, and CD28+ increased while NK cells, B cells, and CD28- decreased in the conventional chemotherapy group (); CD3+, CD4+, CD4+CD8+, B cells, and CD28+ increased while CD8+, NK cells, and CD28- decreased in chrono-chemotherapy group (). The progression-free survival (PFS) of patients in the chrono-chemotherapy group (3.29 ± 0.46 years vs 2.56 ± 0.35 years) was longer (). The quality of life (QOL) score in the chrono-chemotherapy group was higher (64.83 ± 1.54 points vs 51.72 ± 1.89 points) (). The incidences of leukopenia (63.33%) and nausea and vomiting (53.33%) in the conventional chemotherapy group were higher than those in the chrono-chemotherapy group (30.00% and 30.00, respectively) (). The chrono-chemotherapy could improve the cellular immune function of NSCLS patients, prolong their survival period, elevate the QOL, and reduce the side effects.